FindTrial
Sign In

recombinant fowlpox-TRICOM vaccine

BIOLOGICAL5 trials

Sponsors

National Institute on Deafness and Other Communication Disorders (NIDCD), National Cancer Institute (NCI)

Conditions

Bladder AdenocarcinomaBladder Squamous Cell CarcinomaBladder Urothelial CarcinomaHead and Neck CancerMetastatic CancerProstate CancerRecurrent Bladder CarcinomaRecurrent Melanoma

Phase 1

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
TerminatedNCT00030693
National Cancer Institute (NCI)Unspecified Adult Solid Tumor, Protocol Specific
Start: 2001-12-31Updated: 2013-01-24
Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer
CompletedNCT00021424
National Institute on Deafness and Other Communication Disorders (NIDCD)Head and Neck Cancer, Metastatic Cancer
Start: 2001-06-30Updated: 2015-04-30
Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy
TerminatedNCT00072137
National Cancer Institute (NCI)Bladder Adenocarcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma +5
Start: 2003-10-31End: 2010-11-30Updated: 2014-12-23

Phase 2

Vaccine Therapy in Treating Patients With Metastatic Melanoma
TerminatedNCT00087373
National Cancer Institute (NCI)Recurrent Melanoma, Stage IV Melanoma
Start: 2004-06-30Updated: 2014-06-09
153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer
CompletedNCT00450619
National Cancer Institute (NCI)Prostate Cancer
Start: 2007-02-28End: 2012-11-30Updated: 2017-01-04